Loading menu…

Induction of CDC2 Phosphorylation in Skin Biopsies from Patients with Solid Tumors Undergoing DNA-Damaging Chemotherapy

§ Merck & Co., Inc.

Send Message

To: Author

Induction of CDC2 Phosphorylation in Skin Biopsies from Patients with Solid Tumors Undergoing DNA-Damaging Chemotherapy

Article Fingerprint

ReserarchID

E4CZU

Induction of CDC2 Phosphorylation in Skin Biopsies from Patients with Solid Tumors Undergoing DNA-Damaging Chemotherapy Banner

Key Research Insights

Synthesized scholarly intelligence & interactive research assistant
  • English
  • Afrikaans
  • Albanian
  • Amharic
  • Arabic
  • Armenian
  • Azerbaijani
  • Basque
  • Belarusian
  • Bengali
  • Bosnian
  • Bulgarian
  • Catalan
  • Cebuano
  • Chichewa
  • Chinese (Simplified)
  • Chinese (Traditional)
  • Corsican
  • Croatian
  • Czech
  • Danish
  • Dutch
  • Esperanto
  • Estonian
  • Filipino
  • Finnish
  • French
  • Frisian
  • Galician
  • Georgian
  • German
  • Greek
  • Gujarati
  • Haitian Creole
  • Hausa
  • Hawaiian
  • Hebrew
  • Hindi
  • Hmong
  • Hungarian
  • Icelandic
  • Igbo
  • Indonesian
  • Irish
  • Italian
  • Japanese
  • Javanese
  • Kannada
  • Kazakh
  • Khmer
  • Korean
  • Kurdish (Kurmanji)
  • Kyrgyz
  • Lao
  • Latin
  • Latvian
  • Lithuanian
  • Luxembourgish
  • Macedonian
  • Malagasy
  • Malay
  • Malayalam
  • Maltese
  • Maori
  • Marathi
  • Mongolian
  • Myanmar (Burmese)
  • Nepali
  • Norwegian
  • Pashto
  • Persian
  • Polish
  • Portuguese
  • Punjabi
  • Romanian
  • Russian
  • Samoan
  • Scots Gaelic
  • Serbian
  • Sesotho
  • Shona
  • Sindhi
  • Sinhala
  • Slovak
  • Slovenian
  • Somali
  • Spanish
  • Sundanese
  • Swahili
  • Swedish
  • Tajik
  • Tamil
  • Telugu
  • Thai
  • Turkish
  • Ukrainian
  • Urdu
  • Uzbek
  • Vietnamese
  • Welsh
  • Xhosa
  • Yiddish
  • Yoruba
  • Zulu
Reading Preferences
Font Size
Line Spacing
Background
This converted HTML version may contain rendering inconsistencies. Please refer to the PDF for the authoritative version, or click here to provide feedback.

Abstract

This study was to clinically validate phosphorylated CDC2(pCDC2) as a biomarker for Wee1 kinase inhibitors by measuring pCDC2 in skin biopsies from patients receiving DNA damaging chemotherapy. Skin biopsies were performed at scheduled times after chemotherapy. Total CDC2 and pCDC2 in epidermal cells, hair follicle and bulb from skin biopsies were determined using chromogenic multiplex immunohis-tochemistry with multispectral image analysis. Statistical analyses were performed for each cell type after log-transformation of data. Thirty-one patients (29-88 years) completed the study. Significant induction of pCDC2 in response to chemotherapy was detected. Epidermis was most consistently evaluable across skin biopsies, demonstrating strong induction of pCDC2. The percentage of cells positive for total CDC2 and pCDC2 showed a 1.40-fold induction from baseline to 24h post-infusion (p=0.012) and a 2.05-fold increase from baseline to 48h (p

References

15 Cites in Article
  1. 1. O. Hashimoto (2006). Cell cycle regulation by the Wee1 Inhibitor PD0166285, Pyrido [2,3-d] pyimidine, in the B16 mouse melanoma cell line. BMC Cancer, 6(1), 292.
  2. 2. H. Hirai (2009). Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. Molecular Cancer Therapeutics, 8(11), 2992-3000.
  3. 3. H. Hirai (2010). MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil. Cancer Biology & Therapy, 9(7), 514-522.
  4. 4. Takumi Kawabe (2004). G2 checkpoint abrogators as anticancer drugs. Molecular Cancer Therapeutics, 3(4), 513-519.
  5. 5. S. Leijen,J. Beijnen,J. Schellens (2010). Abrogation of the G2 Checkpoint by Inhibition of Wee-1 Kinase Results in Sensitization of p53- Deficient Tumor Cells to DNADamaging Agents. Curr Clin Pharmacol, 5(3), 186-191.
  6. 6. Jun Li,Yuli Wang,Yi Sun,Theodore Lawrence (2002). Wild-Type TP53 Inhibits G2-Phase Checkpoint Abrogation and Radiosensitization Induced by PD0166285, a WEE1 Kinase Inhibitor. Radiation Research, 157(3), 322-330.
  7. 7. S. Mizuarai (2009). Discovery of gene expression-based pharmacodynamic biomarker for a p53 context-specific anti-tumor drug Wee1 inhibitor. Molecular Cancer, 8(1), 34.
  8. 8. Matthew O’connell,Nancy Walworth,Antony Carr (2000). The G2-phase DNA-damage checkpoint. Trends in Cell Biology, 10(7), 296-303.
  9. 9. M. Oken (1982). Toxicity and Response: Criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol, 5, 649-655.
  10. 10. S. Paul (2010). How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nature Reviews Drug Discovery, 9(3), 203-214.
  11. 11. W. Plunkett,P. Huang,Y. Xu,V. Heinemann,R. Grunewald,V. Gandhi (1995). Gemcitabine: metabolism, mechanisms of action, and selfpotentiation. Semin Oncol, 22, 3-10.
  12. 12. Geoffrey Shapiro,J. Harper (1999). Anticancer drug targets: cell cycle and checkpoint control. Journal of Clinical Investigation, 104(12), 1645-1653.
  13. 13. D. Tan (2009). Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development. The Cancer Journal, 15(5), 406-420.
  14. 14. Y. Wang (2001). Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator. Cancer Res, 61, 8211-8217.
  15. 15. J. Yun (1999). p53 Negatively Regulates cdc2 Transcription via the CCAAT-binding NF-Y Transcription Factor. Journal of Biological Chemistry, 274(42), 9677-2968.

Funding

No external funding was declared for this work.

Conflict of Interest

The authors declare no conflict of interest.

Ethical Approval

No ethics committee approval was required for this article type.

Data Availability

Not applicable for this article.

How to Cite This Article

Amy Sun, Raymond L. Lam, Amy Harman, Anna C. Pavlick, Gary A. Herman. 2014. "Induction of CDC2 Phosphorylation in Skin Biopsies from Patients with Solid Tumors Undergoing DNA-Damaging Chemotherapy". Global Journal of Medical Research - K: Interdisciplinary GJMR-K Volume 14 (GJMR Volume 14 Issue 2 (K1)).

More Citation Formats

Download Citation

Journal Specifications

Crossref Journal DOI 10.17406/gjmra

Print ISSN 0975-5888

e-ISSN 2249-4618

Keywords
Classification
GJMR-K Classification NLMC Code: QZ 310
Version of record
v1.2

Issue date
January 20, 2014

Language
English
Order Article Reprint
Experience in AR

Explore published articles in an immersive Augmented Reality environment. Our platform converts research papers into interactive 3D books, allowing readers to view and interact with content using AR and VR compatible devices.

Read in 3D

Your published article is automatically converted into a realistic 3D book. Flip through pages and read research papers in a more engaging and interactive format.

Article Matrices
Total Views: 1.8K
Total Downloads: 110
All Trends

Request Access

Please fill out the form below to request access to this research paper. Your request will be reviewed by the editorial or author team.
X

This is the heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

High-quality academic research articles on global topics and journals.

Induction of CDC2 Phosphorylation in Skin Biopsies from Patients with Solid Tumors Undergoing DNA-Damaging Chemotherapy

Amy Sun
Amy Sun Merck & Co., Inc.
Raymond Lam
Raymond Lam <p>Merck & Co., Inc.</p>
Amy Harman
Amy Harman <p>Merck & Co., Inc.</p>
Anna Pavlick
Anna Pavlick <p>Merck & Co., Inc.</p>
Gary Herman
Gary Herman <p>Merck & Co., Inc.</p>